Current Projects

  • “Interrogating the in vivo antimetastatic action of LMWH tinzaparin and simvastatin in an orthotopic surgical resection mouse model of triple negative breast cancer: towards novel metastasis prevention strategies” SFI; Technology Innovation Development award; 2017-2018 ; €98,950 total award. €110K allocated to Prof Byrne (Collaborator).

    Two  million people die annually from cancer. Low-molecular-weight-heparin (LMWH) prolongs survival in cancer patients with long life-expectancy (early-stage disease) but not advanced malignancy. This suggests that LMWH prevents cancer death by inhibiting cancer-spread (metastasis). LMWHs inhibit metastasis in vivo but causes bleeding. Consequently, LMWH is unlikely to be used for preventing cancer-spread unless bleeding side-effects can be urgently addressed. In work supported by a previous SFI TIDA & recently published following patent application it has been demonstrated that LMWH-Tinzaparin enhanced endothelial-barrier function (which is crucial for preventing metastasis) & reduced tumour trans-endothelial-migration. Strikingly, the endothelial-protective cholesterol-lowering agent simvastatin greatly potentiated the effect of Tinzaparin, permitting endothelial-protection at a much lower concentration. If replicated in vivo, these findings could represent a novel therapeutic approach to inhibiting cancer spread, by delivering the metastasis-preventing properties of LMWH without exposing patients to a high bleeding-risk. There is a large addressable market for this invention & low predicted regulatory barriers: the invention combines existing drugs commonly prescribed in routine practice. The aim of this project is to provide further in vitro evidence and critically, in vivo proof-of-principle for the antimetastatic action of a LMWH/statin combination in a mouse model of breast cancer.

 

GLIOTRAIN European Training Network offers 15 PhD positions

GLIOTRAIN: “Exploiting GLIOblastoma intractability to address European research TRAINing needs in translational brain tumour research, cancer systems medicine and integrative multi-omics” Horizon 2020-MSCA-ITN-2017; 2017; €3.8 million (total) – RCSI allocated €1.3 million. Co-ordinator & PI; Glioblastoma (GBM) is the most frequent, aggressive and lethal brain tumour. It has a universally fatal prognosis with 85% of patients dying within two years. New treatment options and precision medicine therapies are required. This must be achieved by multi-sectoral industry-academia collaborations in newly emerging, innovative research disciplines. The research objective of GLIOTRAIN is to identify novel therapeutic strategies for GBM, implementing NGS, systems medicine and integrative multi-omics to unravel disease resistance mechanisms. Research activities incorporate applied systems medicine, integrative multi-omics and translational cancer biology implementing clinically relevant models. The consortium brings together leading European and international academics, clinicians, private sector and not-for-profit partners across GBM fields of tumour biology, multiomics, drug development, clinical research, bioinformatics, computational modelling and systems biology. Thus, GLIOTRAIN will address currently unmet translational research and clinical needs in the GBM field by interrogating innovative therapeutic strategies and improving the mechanistic understanding of disease resistance. The ETN will train 15 innovative, creative and entrepreneurial ESRs. The GLIOTRAIN ETN addresses current needs for researchers trained in an environment that spans translational research, medicine and computational biology, and that can navigate confidently between clinical, academic and private sector environments to progress applied research findings towards improved patient outcomes.

COLOSSUS: “Advancing a Precision Medicine Paradigm in metastatic Colorectal Cancer: Systems based patient stratification solutions”. Horizon 2020 – Societal challenges Personalized Medicine Call SC1-PM-02-2017; €6 million total – RCSI allocated €1.3 million Co-ordinator & PIColorectal cancer (CRC) is the third most common cancer in Europe. It is estimated that 50-55% harbour RAS mutations. Current treatment for RAS mutant (mt) metastatic (m) CRC is based on 5-fluoruracil based chemotherapy +/- bevacizumab. There are limited treatment options once cancers become resistant. Targeted treatment of microsatellite stable (MSS) RAS mt disease is difficult and has not evolved significantly in recent years. COLOSSUS will deliver novel concepts for disease-mechanism based patient stratification in MSS RAS mt mCRC to address the need for stratified or personalised therapies. The consortium will integrate multidimensional and longitudinal omics data to identify new MSS RAS mt specific subtypes. Systems biomedicine, network analysis and computational modelling will identify new actionable pathways, biomarkers and targets across subtypes. These targets will be interrogated in pre-clinical patient derived xenograft studies. Newly described MSS RAS mt classifiers will be validated within the COLOSSUS trial. SME partners will develop clinically relevant and commercially viable assays for outcome prediction and stratification of MSS RAS mt patients based on novel classifiers. The impact of assays on CRC associated healthcare costs will be assessed. Patient associations will be included and the proposal will consider regulatory aspects and commercialisation opportunities, in particular for participating SMEs.

Intracranial Patient Derived Xenograft cancer model systems for the development of personalised therapeutics and biomarkers; RCSI Industry Seed Fund; 2017; €128635 total, with €109,599 allocated to Prof Byrne. Glioblastoma (GBM) is the most frequent, and lethal of all brain tumours. 85% of patients die within two years. Moreover, up to 50% of all non-­‐small cell lung cancer (NSCLC) patients (accounting for 85% of all lung cancers) develop brain metastases. The prognosis of these patients is poor with a median survival of 1 year. Thus, there exists a critical need for improved therapies in these settings. In collaboration with Champions Oncology we seek to establish for the first time within Ireland an intracranial PDX platform for interrogation of new brain tumour precision medicine therapies, predictive/ prognostic biomarkers and diagnostics, and emergence of new IP. PDX models are increasingly being used to address clinically relevant questions. Herein, we will establish 25 PDX models to guide biomarker and drug development strategies across GBM and lung cancer brain metastases (LCBM). A new imageable LCBM PDX model will deliver further IP opportunities.

EDIREX: EurOPDX Distributed Infrastructure for Research on patient-derived cancer Xenografts; EU; Horizon 2020 – Research Infrastructure; 2017; Total Award €5 million. €170,608 allocated to RCSI – Prof Byrne. The overall goal of the EDIReX project is to establish a distributed European infrastructure for trans-national access to patient-derived cancer xenograft models and related data, for academic and industrial, preclinical and translational cancer research. Cancer is one of the major causes of death in Europe. Therefore identification, validation and optimisation of therapeutic strategies to improve survival and quality of life of cancer patients still represent a major public health challenge. Most novel therapies fail at the clinical trial stage, due to poor efficacy or to limited numbers of responding patients. Immortalised cancer cell lines cannot interrogate the complexity of human tumours and provide only determinate insights into human disease because they are limited in number and diversity, and have been cultured on plastic over decades. In this view, faithful preclinical models to reliably predict treatment efficacy and discover biomarkers are needed for optimal development of new therapeutic strategies for cancer patients. The role of RCSI in this project is to provide access to significant expertise in advanced pre-clinical imaging. Specifically, selected PDX models for which response data are known, will be implanted orthotopically and imaged (Ultrasound, PET, CT, BL). Imaging response data will be entered into the EDIReX database, which will incorporate Digital Imaging and Communications in Medicine (DICOM) standards. In this way it will be possible to compare responses assessed by imaging and calliper in simpler models, and to further compare them with images of orthotopic implants. RCSI will also participate in networking activities.

Enterprise Ireland Proposal Preparation Support. Coordinators Support award; MSCA- ITN 2017 Co-ordinators Support Award; 2016; €12,395 (total & allocated to Applicant) – PI “Preparation Support for Coordinator” Grant from Enterprise Ireland for support for the MSCA-ITN application for GLIOTRAIN that Dr Byrne coordinated.

ColoForetell; SFI; Career development award; 2014-2018; 629,241€ (total & allocated to Applicant) – PI. The ColoForetell project has identified as a primary goal, the discovery & verification of predictive pharmaco-omic & imaging methods for regorafenib in mCRC patients who have disease progression despite all currently available standard therapies.
Within the current context, a state of the art mCRC Patient Derived Xenograft (PDX) platform will be rolled out at RCSI to enable the systematic and integrated interrogation of predictive ‘omic and imaging markers of intrinsic resistance to regorafenib. Emergent pre-clinical biomarker data will be cross-validated with biomarker candidates arising from genomic biomarker discovery studies implementing ‘CORRECT’ Trial primary tumour biopsy samples (work to be undertaken by industry collaborators at Bayer Healthcare Pharmaceuticals). Data will be integrated and analysed using conventional statistics and where appropriate, systems modeling approaches. Our ultimate goal is the emergence of integrated prognostic tools for the early prediction of patient outcome following REG treatment. The Coloforetell initiative seeks to exploit a multi-dimensional modular strategy towards the focused identification of efficacy biomarkers, to predict patient response to REG therapy in mCRC where response rate heterogeneity has been confirmed. This integrative approach expands on the integrative paradigm employed in the multi-million Euro EU funded ‘ANGIOPREDICT’ initiative (which is co-ordinated by the Applicant) to employ mCRC PDX modelling and molecular imaging as state of the art tools in pre-clinical biomarker identification.

 

 

Comments are closed.